FDA approves pediatric neuroblastoma drug based on Penn State professor’s work

By |2023-12-15T08:07:56-05:00December 15th, 2023|

Giselle Saulnier Sholler, professor of pediatrics and of pharmacology, reflects on 20 years working to change cancer outcomes for children HERSHEY, Pa. — In 2003, the first year of her fellowship in pediatric oncology, two of Giselle Saulnier Sholler’s first three patients had died from neuroblastoma, closely matching the 30% survival rate expected at the [...]

US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer

By |2023-12-15T08:08:24-05:00December 15th, 2023|

LOUISVILLE, Ky.--(BUSINESS WIRE)--USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk neuroblastoma. IWILFIN is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial [...]

Go to Top